Carcinoembryonic antigen (CEA) is a protein usually produced in the developing fetus and disappears or is absent in adults. Abnormal amounts of this protein may lead to cancer. CEA test is performed to measure the level of proteins and check for the recurrence of colon and other cancers in patients already diagnosed with cancer. The normal accepted range of this protein is 0 micrograms to 0.25 micrograms per liter. Elevated levels of CEA in the patients recently treated for cancer, indicates recurrence of the cancer.
These elevated levels are attributed to different types of cancers and other conditions such as cholecystitis, lung infection, heavy smoking, inflammatory bowel diseases, peptic ulcer, etc. High levels of CEA are also found in the patients who are not diagnosed with cancer which might increase the risk of acquiring cancer. Hematoma (blood accumulating under the skin), infection, dizziness and excessive bleeding are some of the risks associated with abnormal levels of CEA. The abnormal levels of CEA in the body can be detected by using arcitumomab a monoclonal antibody; these are commonly used in the identification of glycoprotein expression in tissue samples.
Request to View Brochure of Report -
The continuous technological advances followed by discovery of specific antigens, biomarkers, and etc. form the prime reason for tremendous growth of CEA Testing Market. The market can be segmented by instrumentation and on the basis of number of tests performed in specific geographies elucidating the market by volume and geography. Qualitative analysis of the regulatory policies and patent protection can highlight the need of CEA testing market.
The major factors influencing the growth of the market are rise in geriatric population, technological breakthroughs that aids in revealing the genetic basis of the disease, increased accuracy of the diagnostic procedures and rigorous research and development initiatives. Lack of awareness and availability of novel technological solutions might pose a challenge to the growth of CEA testing market. The companies competing in this market are Abbott Laboratories, Siemens Healthcare, bioMerieux, Danaher Corporation (Beckman Coulter), Myriad Genetics, Epigenomics, Qiagen N.V., and Life Technologies Corporation.
Comments
Post a Comment